Role of Circadian Misalignment in Beta-cell Failure in Type 2 Diabetes
INSTITUTION
Mayo Clinic Rochester, MN
PRINCIPAL INVESTIGATOR
Matveyenko, Aleksey V (Contact)
FUNDING
$517K
YEAR
2013
MOONBASE SCORE
Still being scored
LOADING MOONBASE SCORE
Abstract
PROJECT SUMMARY/ABSTRACT Pancreatic β-cell failure in a distinctive feature of Type 2 diabetes mellitus (T2DM) and therefore preservation of β-cell health has been identified as a critical barrier for the development of successful preventative and treatment strategies in T2DM. Primary features of β-cell failure include insulin secretory dysfunction, loss of transcriptional identity/β-cell dedifferentiation, and β-cell loss, with growing evidence pointing to impaired endoplasmic reticulum (ER) proteostasis as a key driver of this process. Recent evidence suggests that environmental stress conditions that produce disruptions of daily fasting/feeding circadian cycles (i.e. circadian disruption, CD) lead to glucose intolerance, hyperglycemia, and promote β-cell failure in T2DM. However, the molecular mechanisms underlying circadian control of β-cell function and ER proteostasis remain unknown. In this regard, our preliminary studies determined that CD-mediated abrogation of normal fasting/feeding cycles is a potent physiological inducer of β- cell functional failure, and this process is molecularly mediated through loss of β-cell expression/activity of circadian transcription factor D-box binding PAR bZIP transcription factor (Dbp). Therefore, the key objective of the proposal is to test the hypothesis that Dbp is an important regulator of β-cell circadian function through rhythmic activation of transcripts regulating insulin secretion and ER proteostasis, whereas loss of Dbp expression, as occurs in β-cells in response to circadian disruption and diet-induced obesity, promotes β-cell functional decline in T2DM. To address this, Specific Aim 1 will utilize novel conditional genetic loss and gain-of- function Dbp mouse models to establish a causative relationship between circadian Dbp expression and the regulation of β-cell function, ER proteostasis, and transcriptional identity. In addition, we will also examine whether Dbp regulates β-cell function and transcription in human β-cells utilizing viral gain/loss of function techniques concurrent with transplantation of human stem cell-derived β-cells into immunodeficient mice. Specific Aim 2 will utilize β-cell-specific Dbp luciferase reporter mice and systems biology multiomics approaches (RNAseq + scATAC seq) to 1) identify molecular mechanisms by which obesity disrupts circadian regulation of Dbp expression and corresponding β-cell circadian clock function, and 2) test novel strategies designed to restore normal functionality of β-cell circadian clocks in obesity as means to prevent β-cell failure in T2DM. Taken together, successful completion of proposed studies will uncover novel molecular mechanisms through which β- cells integrate and respond to circadian changes in nutritional availability and will provide potential therapeutic targets for prevention and treatment of T2DM.
Are you the primary organization running this research?
The two tools below are built for the principal investigator & host institution behind this project.